desloratadin +pharma 5mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 15575 desloratadin - potahovaná tableta - 5mg - desloratadin
infectoscab 50mg/g krém
infectopharm arzneimittel und consilium gmbh, heppenheim array - 9325 permethrin - krém - 50mg/g - permethrin
propofol mct fresenius 20mg/ml injekční/infuzní emulze v předplněné injekční stříkačce
fresenius kabi deutschland gmbh, bad homburg array - 8934 propofol - injekční/infuzní emulze v předplněné injekční stříkačce - 20mg/ml - propofol
sufentanil torrex 5mcg/ml injekční roztok
chiesi pharmaceuticals gmbh, vídeň array - 11995 sufentanil-citrÁt - injekční roztok - 5mcg/ml - sufentanil
sufentanil torrex 50mcg/ml injekční roztok
chiesi pharmaceuticals gmbh, vídeň array - 11995 sufentanil-citrÁt - injekční roztok - 50mcg/ml - sufentanil
tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
akistan duo 50mcg/ml+5mg/ml oční kapky, roztok
pharmaselect international beteiligungs gmbh, vídeň array - 12369 latanoprost; 2696 timolol-maleinÁt - oční kapky, roztok - 50mcg/ml+5mg/ml - timolol, kombinace
atenobene 25mg potahovaná tableta
ratiopharm gmbh, ulm array - 4442 atenolol - potahovaná tableta - 25mg - atenolol
atenobene 50mg potahovaná tableta
ratiopharm gmbh, ulm array - 4442 atenolol - potahovaná tableta - 50mg - atenolol
berodual 0,25mg/ml+0,5mg/ml roztok k rozprašování
boehringer ingelheim international gmbh, ingelheim am rhein array - 2035 monohydrÁt ipratropium-bromidu; 2219 fenoterol-hydrobromid - roztok k rozprašování - 0,25mg/ml+0,5mg/ml - fenoterol a ipratropium-bromid